Medigene AG: Medigene participates at upcoming conferences

Planegg/Martinsried (pta011/09.11.2021/07:30 UTC+1) Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, will participate at the following upcoming financial and scientific conferences. Medigene's management and/or scientists will be available for one-on-one meetings at these events.

SITC 2021 - The Society for Immunotherapy of Cancer's 36th Annual Meeting
10-14 November 2021
https://www.sitcancer.org/education/annualmeeting

12th Annual Jefferies Global Healthcare Conference
16-18 November 2021
https://www.jefferies.com/IdeasAndPerspectives/Conferences/325/111621

Cell Immunotherapies for Solid Tumors Summit
16-18 November 2021
https://solid-tumors-summit.com/

ESMO Immuno-Oncology Congress 2021
8-11 December 2021
https://www.esmo.org/meetings/esmo-immuno-oncology-congress-2021

11th Annual LifeSci Partners Corporate Access Event
5-7 January 2022

--- end of press release ---

About Medigene
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Planegg/Martinsried near Munich, Germany. With its scientific expertise, Medigene is working on the development of innovative immunotherapies to enhance T cell activity against solid cancers in fields of high unmet medical need. Medigene's pipeline includes preclinical as well as clinical programs in development.
Medigene's strategy is to develop its own therapies towards clinical proof-of-concept. In addition, the Company offers selected partners the opportunity to discover and develop therapies on the basis of its proprietary technology platforms. In return for such partnerships, Medigene expects to receive upfront and milestone payments as well as research and development funding and royalties on future product sales.
For more information, please visit https://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene
Dr. Anna Niedl
Phone: +49 89 2000 3333 01
e-mail: investor@medigene.com

LifeSci Advisors
Mary-Ann Chang
Phone: +44 7483 284 853
e-mail: mchang@lifesciadvisors.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg/Martinsried Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 2000 3333 01
E-Mail:	investor@medigene.com
Website:	www.medigene.com
ISIN(s):	DE000A1X3W00 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate